|
|
First 100 cases of transvesical single-port robotic radical prostatectomy |
Roxana Ramos-Carpinteyro,Ethan L. Ferguson,Jaya S. Chavali,Albert Geskin,Jihad Kaouk*( )
|
Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA |
|
|
Abstract Objective: To describe the surgical technique and report the early outcomes of the transvesical (TV) approach to single-port (SP) robot-assisted radical prostatectomy. Methods: All procedures were performed at a single center by one surgeon. We identified the first 100 consecutive patients with clinically localized prostate cancer that underwent SP TV robot-assisted radical prostatectomy using the da Vinci SP robotic surgical system. Data were collected prospectively and analyzed with descriptive statistics. The primary outcomes assessed were postoperative urinary continence, rate of biochemical recurrence, and sexual function. Results: All procedures were performed without extra ports or conversion. The median age was 62.1 years and 49.0% of the patients had abdominal surgery history. The preoperative median prostate-specific antigen value and prostate volume were 5.0 ng/mL and 33.0 mL, respectively. There were no intraoperative complications. The median operative time and estimated blood loss were 212.5 min and 100.0 mL, respectively. A total of 92.0% of patients were discharged within 24.0 h, with an overall median length of stay of 5.6 h. Only 4.0% of patients required opioid prescriptions at discharge. The median Foley catheter duration was 3 days. Positive margins were present in 15.0% of cases. Median follow-up was 10.4 months. Continence rate was immediate after Foley removal in 49.0% of cases, 65.0% at 2 weeks, 77.4% at 6 weeks, 94.1% at 6 months, and 98.9% at 1 year. One case of biochemical recurrence (1.0%) was noted 3 months after surgery. Conclusion: The SP TV approach for radical prostatectomy cases is a safe and feasible technique for patients with clinically localized prostate cancer. This technique offers advantages of short hospital stay, minimal narcotic use postoperatively, and promising early return of urinary continence, without compromising oncologic outcomes.
|
Received: 08 September 2022
Available online: 20 October 2023
|
Corresponding Authors:
*E-mail address: kaoukj@ccf.org (J. Kaouk).
|
|
|
|
Patient preparation. (A) Dorsal decubitus position, parallel to the ground; (B) Suprapubic midline single incision of 3.5 cm.
|
|
Access port and robot docking. (A) Da Vinci SP access port; (B) Docked robot; (C) Robot inside bladder illustration.
|
|
Transvesical dissection and vesico-urethral anastomosis. (A) Posterior dissection illustration; (B) Posterior dissection; (C) Vas deferens transection (right); (D) Seminal vesicle artery ligation (left); (E) Anterior dissection; (F) Vascular pedicle ligation (left); (G) Vascular pedicle ligation (left) illustration; (H) Dorsal venous complex ligation; (I) Urethral transection; (J) Pulling prostate into bladder; (K) Lymph node dissection (right); (L) Anastomosis beginning at 6 o’clock; (M) Anastomosis illustration; (N) Complete anastomosis, inflated Foley catheter balloon, specimen resting on bladder.
|
|
Postoperative scar.
|
Demographic and baseline characteristics | Value | Age, median (Q1, Q3), year | 62.1 (58.1, 66.3) | BMI, median (Q1, Q3), kg/m2 | 28.1 (25.2, 31.3) | Charlson comorbidity index, n (%) | 2 (90% estimated 10-year survival) | 1 (1.0) | 3 (77% estimated 10-year survival) | 32 (32.0) | 4 (53% estimated 10-year survival) | 40 (40.0) | 5 (21% estimated 10-year survival) | 21 (21.0) | ≥6 (<2% estimated 10-year survival) | 6 (6.0) | History of abdominal surgery, n (%) | 49 (49.0) | ASA classification, median (Q1, Q3) | 3 (2, 3) | SHIM score, median (Q1, Q3) | 19 (8, 23) | PSA, median (Q1, Q3), ng/mL | 5.0 (4.0, 8.0) | Prostate volume, median (Q1, Q3), mL | 33.0 (25.0, 43.2) | Gleason score, n (%) | 6 | 29 (29.0) | 7 (3+4) | 48 (48.0) | 7 (4+3) | 18 (18.0) | 8 | 3 (3.0) | 9 | 2 (2.0) | PI-RADSa, n (%) | 2 | 2 (2.9) | 3 | 9 (13.2) | 4 | 30 (44.1) | 5 | 27 (39.7) | NCCN risk group, n (%) | Very low | 1 (1.0) | Low | 25 (25.0) | Intermediate | 69 (69.0) | High | 2 (2.0) | Very high | 3 (3.0) |
|
Demographic and baseline characteristics (n=100).
|
Perioperative and pathology outcomes | Value | Estimated blood loss, median (Q1, Q3), mL | 100 (50, 150) | Operative time, median (Q1, Q3), min | 212.5 (188.0, 238.8) | Nerve-sparing, n (%) | 77 (77.0) | Lymphadenectomy, n (%) | 43 (43.0) | Intraoperative complications, n (%) | 0 (0) | Postoperative complications, n (%) | 16 (16.0) | Clavien-Dindo I | 12 (12.0) | Clavien-Dindo II | 2 (2.0) | Clavien-Dindo IIIa | 2 (2.0) | Length of stay, median (Q1, Q3), h | 5.6 (4.1, 21.9) | Pain medications discharge, n (%) | 53 (53.0) | NSAIDs | 49 (49.0) | Opioids | 4 (4.0) | Readmission, n (%) | 6 (6.0) | Foley catheter, median (Q1, Q3), day | 3 (3, 4) | Specimen weight, median (Q1, Q3), g | 40.0 (35.0, 49.5) | Extra-prostatic extension, n (%) | 38 (38.0) | Bladder neck invasion, n (%) | 6 (6.0) | Lymphovascular invasion, n (%) | 7 (7.0) | Seminal vesicle invasion, n (%) | 7 (7.0) | Positive margin, n (%) | 15 (15.0) |
|
Perioperative and pathology outcomes (n=100).
|
|
Percentage of continent patients after transvesical single-port robot-assisted radical prostatectomy.
|
|
Sexual function after transvesical single-port robot-assisted radical prostatectomy. ED, erectile dysfunction; PDE5, phosphodiesterase-5; SHIM, Sexual Health Inventory for Men.
|
[1] |
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375:1415. https://doi.org/10.1056/NEJMoa1606220.
doi: 10.1056/NEJMoa1606220
|
[2] |
Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. AUA/ASTRO guideline on clinically localized prostate cancerdpart I: introduction, risk assessment, staging, and risk-based management. J Urol 2022. https://doi.org/10.1097/JU.0000000000002757.
|
[3] |
Schaeffer EM, Srinivas S, An Y, Armstrong AJ, Barocas D, Chapin B, et al. Version 4.2022 of the NCCN guidelines for prostate cancer. NCCN 2022. https://www.nccn.org/guidelines/guidelinesdetail?categoryZ1&idZ1459. [Accessed 25 August 2022].
|
[4] |
Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, et al. Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an American Urological Association/American Society for Radiation Oncology/ Society of Urologic Oncology guideline. J Clin Oncol 2018; 36:3251. https://doi.org/10.1200/JCO.18.00606.
doi: 10.1200/JCO.18.00606
pmid: 30183466
|
[5] |
Sooriakumaran P, Srivastava A, Shariat SF, Stricker PD, Ahlering T, Eden CG, et al. A multinational, multi-institutional study comparing positive surgical margin rates among 22 393 open, laparoscopic, and robot-assisted radical prostatectomy patients. Eur Urol 2014; 66:450-6.
doi: 10.1016/j.eururo.2013.11.018
pmid: 24290695
|
[6] |
Kaouk J, Garisto J, Sagalovich D, Dagenais J, Bertolo R, Klein E. Robotic single-port partial prostatectomy for anterior tumors: transvesical approach. Urology 2018; 118:242. https://doi.org/10.1016/j.urology.2018.03.034.
doi: S0090-4295(18)30291-7
pmid: 29704582
|
[7] |
Kaouk J, Sawczyn G, Wilson C, Aminsharifi A, Fareed K, Garisto J, et al. Single-port percutaneous transvesical simple prostatectomy using the SP robotic system: initial clinical experience. Urology 2020; 141:173-7.
doi: S0090-4295(20)30261-2
pmid: 32171697
|
[8] |
Kaouk J, Beksac AT, Abou Zeinab M, Duncan A, Schwen ZR, Eltemamy M. Single port transvesical robotic radical prostatectomy: initial clinical experience and description of technique. Urology 2021; 155:130-7.
doi: 10.1016/j.urology.2021.05.022
pmid: 34038749
|
[9] |
Ng CF, Teoh JY, Chiu PK, Yee CH, Chan CK, Hou SS, et al. Robot-assisted single-port radical prostatectomy: a phase 1 clinical study. Int J Urol 2019; 26:878-83.
doi: 10.1111/iju.14044
pmid: 31257704
|
[10] |
Gandaglia G, Martini A, Ploussard G, Fossati N, Stabile A, De Visschere P, et al. External validation of the 2019 Briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection. Eur Urol 2020; 78:138-42.
doi: S0302-2838(20)30198-6
pmid: 32268944
|
[11] |
Woodall WH, Rakovich G, Steiner SH. An overview and critique of the use of cumulative sum methods with surgical learning curve data. Stat Med 2021; 40:1400-13.
doi: 10.1002/sim.8847
pmid: 33316849
|
[12] |
Lenfant L, Sawczyn G, Aminsharifi A, Kim S, Wilson CA, Beksac AT, et al. Pure single-site robot-assisted radical prostatectomy using single-port versus multiport robotic radical prostatectomy: a single-institution comparative study. Eur Urol Focus 2020; 7:964-72.
|
[13] |
Rosenberg JE, Jung JH, Edgerton Z, Lee H, Lee S, Bakker CJ, et al. Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer. Cochrane Database Syst Rev 2020; 8:CD013641. https://doi.org/10.1002/14651858.CD013641.pub2.
|
[1] |
Enrico Checcucci, Alberto Piana, Gabriele Volpi, Pietro Piazzolla, Daniele Amparore, Sabrina De Cillis, Federico Piramide, Cecilia Gatti, Ilaria Stura, Enrico Bollito, Federica Massa, Michele Di Dio, Cristian Fiori, Francesco Porpiglia. Three-dimensional automatic artificial intelligence driven augmented-reality selective biopsy during nerve-sparing robot-assisted radical prostatectomy: A feasibility and accuracy study[J]. Asian Journal of Urology, 2023, 10(4): 407-415. |
[2] |
Umberto Carbonara, Giuseppe Lippolis, Luciano Rella, Paolo Minafra, Giuseppe Guglielmi, Antonio Vitarelli, Giuseppe Lucarelli, Pasquale Ditonno. Intermediate-term oncological and functional outcomes in prostate cancer patients treated with perineal robot-assisted radical prostatectomy: A single center analysis[J]. Asian Journal of Urology, 2023, 10(4): 423-430. |
[3] |
Angelo Territo, Alessandro Uleri, Andrea Gallioli, Josep Maria Gaya, Paolo Verri, Giuseppe Basile, Alba Farré, Alejandra Bravo, Alessandro Tedde, Óscar Rodríguez Faba, Joan Palou, Alberto Breda. Robot-assisted oncologic pelvic surgery with Hugo™ robot-assisted surgery system: A single-center experience[J]. Asian Journal of Urology, 2023, 10(4): 461-466. |
[4] |
Thomas Whish-Wilson, Jo-Lynn Tan, William Cross, Lih-Ming Wong, Tom Sutherland. Prostate magnetic resonance imaging and the value of experience: An intrareader variability study[J]. Asian Journal of Urology, 2023, 10(4): 488-493. |
[5] |
Thitipat Hansomwong, Pat Saksirisampant, Sudhir Isharwal, Pubordee Aussavavirojekul, Varat Woranisarakul, Siros Jitpraphai, Sunai Leewansangtong, Tawatchai Taweemonkongsap, Sittiporn Srinualnad. Role of preoperative magnetic resonance imaging on the surgical outcomes of radical prostatectomy: Does preoperative tumor recognition reduce the positive surgical margin in a specific location? Experience from a Thailand prostate cancer specialized center[J]. Asian Journal of Urology, 2023, 10(4): 494-501. |
[6] |
Kerri R. Beckmann, Michael E. O'Callaghan, Andrew D. Vincent, Kim L. Moretti, Nicholas R. Brook. Clinical outcomes for men with positive surgical margins after radical prostatectomy—results from the South Australian Prostate Cancer Clinical Outcomes Collaborative community-based registry[J]. Asian Journal of Urology, 2023, 10(4): 502-511. |
[7] |
Wei He,Yutian Xiao,Shi Yan,Yasheng Zhu,Shancheng Ren. Cell-free DNA in the management of prostate cancer: Current status and future prospective[J]. Asian Journal of Urology, 2023, 10(3): 298-316. |
[8] |
Shulin Wu,Sharron X. Lin,Kristine M. Cornejo,Rory K. Crotty,Michael L. Blute,Douglas M. Dahl,Chin-Lee Wu. Clinicopathological and oncological significance of persistent prostate-specific antigen after radical prostatectomy: A systematic review and meta-analysis[J]. Asian Journal of Urology, 2023, 10(3): 317-328. |
[9] |
Stefano Alba,Deborah Fimognari,Fabio Crocerossa,Luigi Ascalone,Carmine Pullano,Fernando Chiaravalloti,Francesco Chiaradia,Umberto Carbonara,Matteo Ferro,Ottavio de Cobelli,Vincenzo Pagliarulo,Giuseppe Lucarelli,Michele Battaglia,Rocco Damiano,Francesco Cantiello. Neuraxial anesthesia versus general anesthesia in patients undergoing three-dimensional laparoscopic radical prostatectomy: Preliminary results of a prospective comparative study[J]. Asian Journal of Urology, 2023, 10(3): 329-336. |
[10] |
Fabricio B. Carrerette,Daniela B. Rodeiro,Rui T. F. Filho,Paulo A. Santos,Celso C. Lara,Ronaldo Damião. Randomized controlled trial comparing open anterograde anatomic radical retropubic prostatectomy with retrograde technique[J]. Asian Journal of Urology, 2023, 10(2): 151-157. |
[11] |
Sat Prasad Nepal,Takehiko Nakasato,Takashi Fukagai,Yoshio Ogawa,Yoshihiro Nakagami,Takeshi Shichijo,Jun Morita,Yoshiko Maeda,Kazuhiko Oshinomi,Tsutomu Unoki,Tetsuo Noguchi,Tatsuki Inoue,Ryosuke Kato,Satoshi Amano,Moyuru Mizunuma,Masahiro Kurokawa,Yoshiki Tsunokawa,Sou Yasuda. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer[J]. Asian Journal of Urology, 2023, 10(2): 158-165. |
[12] |
Hua Gong,Kang Chen,Lan Zhou,Yongchao Jin,Weihua Chen. Deleted in liver cancer 1 suppresses the growth of prostate cancer cells through inhibiting Rho-associated protein kinase pathway[J]. Asian Journal of Urology, 2023, 10(1): 50-57. |
[13] |
Leandro Blas,Masaki Shiota,Shohei Nagakawa,Shigehiro Tsukahara,Takashi Matsumoto,Ken Lee,Keisuke Monji,Eiji Kashiwagi,Junichi Inokuchi,Masatoshi Eto. Validation of user-friendly models predicting extracapsular extension in prostate cancer patients[J]. Asian Journal of Urology, 2023, 10(1): 81-88. |
[14] |
Donghua Xie,Di Gu,Ming Lei,Cong Cai,Wen Zhong,Defeng Qi,Wenqi Wu,Guohua Zeng,Yongda Liu. The application of indocyanine green in guiding prostate cancer treatment[J]. Asian Journal of Urology, 2023, 10(1): 1-8. |
[15] |
Liang G. Qu,Gregory Jack,Marlon Perera,Melanie Evans,Sue Evans,Damien Bolton,Nathan Papa. Impact of delay from transperineal biopsy to radical prostatectomy upon objective measures of cancer control[J]. Asian Journal of Urology, 2022, 9(2): 170-176. |
|
|
|
|